Methods of inhibiting platelet anti-HLA alloimmune antibody...

Details Methods of inhibiting platelet anti-HLA alloimmune antibody... Methods of inhibiting platelet anti-HLA alloimmune antibody...

2006-08-08

2006-08-08

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S885000, C424S085100, C424S278100, C530S350000, C530S351000

Reexamination Certificate

active

07087573

ABSTRACT:
The invention relates to a method for inhibiting an in vivo alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In particular, a soluble 18 KDa recombinant CD40L is used to inhibit an in vivo alloimmune response.

REFERENCES:
patent: 5540926 (1996-07-01), Aruffo
patent: 6264951 (2001-07-01), Armitage et al.
patent: 6376459 (2002-04-01), Aruffo et al.
patent: 6440418 (2002-08-01), Black et al.
patent: 2001/0026932 (2001-10-01), Thomas et al.
Harrington et al. Vox Sang. 51 (suppl L):18-21 (1986).
Lazaraus Transfusion 39:818-823 (1999).
Nannizzi-Alaimo et al. Circulation 105:2849-2854 (2002).
Semple et al. Blood 100: 1055-1059 (2002).
Bankert et al. Trends in Immunology 22:386-393 (2001.
Krishna et al. Arthritis & Rheumatism 42: 871-881, 1999.
Ludewig et al. Eur. J. Immunol. 26: 3137-3143, 1996.

Affiliated with

Also associated with

Rating

Methods of inhibiting platelet anti-HLA alloimmune antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting platelet anti-HLA alloimmune antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting platelet anti-HLA alloimmune antibody... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3669705